Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04435015
Other study ID # 2000028279
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received
Last updated
Start date November 2021
Est. completion date December 31, 2021

Study information

Verified date May 2022
Source Yale University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary aim of this study is to determine whether Camostat mesylate reduces SARS-COV-2 associated coagulopathy. Additional aims are to determine the effect of Camostat mesylate on SARS-COV-2 associated myocardial injury, to assess duration of hypoxia or intubation, to evaluate the length of intensive care unit and hospital stay, and assess mortality rates.


Description:

The trial is in-patient only. Participants are identified by the hospital physicians and house staff, and contacted by research study personnel. Potential participants fulfilling inclusion criteria and not fulfilling exclusion criteria who agree to participate and sign the informed consent undergo the enrollment process. Ono Pharmaceutical, Japan, will provide Camostat mesylate tablets. The Yale New Haven Hospital research pharmacy will receive and store the drug within 15-25C range according to protocol storage requirements. Microcrystalline Cellulose NF (PH-102) for placebo formulation will be acquired from Fagron. Empty gelatin capsules Size 0, for over-encapsulation will be acquired from Fagron. Before Ono Pharmaceutical can send the drug, an IND will be obtained from the FDA. Principal Investigator and the Yale New Haven Hospital research pharmacy will keep accountability records for all investigational products acquired, dispensed, used and disposed. Drugs are administered by nurses. There will be no restriction on taking other medications, activities or food intake. There are two arms to the study: (a) pharmacy-formulated placebo 3 times a day (b) 200 mg Camostat mesylate to be taken three times daily. Each arm will have 100 subjects. All patients will receive treatment until discharged. Participants will be randomized equally to Camostat mesylate or identical appearing placebo using a permuted-block design with variable block size. The actual treatment assignment will be concealed from the investigators and the participants. The randomization scheme will be generated by the statistical group. Participants have the option of refusing study drug. If the participant decides to stop the drug or blood drawing he or she would be dropped from the trial.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. . Positive COVID-19 test result. 2. Diagnosis of COVID-19 associated coagulopathy and cardiac complications based on D-Dimer, fibrinogen, TnT, CTPE, ischemic EKG changes 3. Provision of informed consent. In patients with altered mental status consents can be obtained from the power of attorney. 4. Stated willingness to comply with all study procedures and availability for the duration of the study 5. Male or female, age 18 or older 6. Diagnosed with hypoxia requiring intubation or positive air pressure. 7. Diagnose with DVT/PE by ultrasound and CTPE and/or 8. Elevated D-Dimer and/or 9. Greater than 2-fold increase in TnT 10. Ischemic EKG changes with ST depression or elevation more than 1 mm in 2 consecutive leads 11. Ability to administer oral medication. Exclusion Criteria: 1. GFR<30 mL/min 2. Severe bleeding requiring blood transfusion of drop of 5% in HCT. 3. Pregnancy or lactation 4. Known allergic reactions to components of Camostat mesylate. 5. Subjects under age 18

Study Design


Intervention

Drug:
Camostat Mesylate
Participants will be given Camostat mesylate three times daily.
Microcrystalline Cellulose, NF
Participants will be given Microcrystalline Cellulose (placebo) three times daily.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Yale University Ono Pharmaceutical Co. Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Percent change in plasma D-Dimer The sum percent change in D-Dimer over 7 days will be compared to day 1 7 days
Secondary Overall Safety and adverse event The first assessment on mortality and complications will be carried out 3 months after the start of the study. 3 months
Secondary Change in plasma Fibrinogen levels Percent change in fibrinogen over 7 days compared to day 1 7 days
Secondary Change in plasma troponin Percent change in troponin over 7 days compared to day 1 7 days
Secondary New onset cardiomyopathy New onset cardiomyopathy defined by a reduction of EF by greater than 10% or less than 45% will be measured 7 days
Secondary Duration of intubation Days with hypoxia (Room Air O2 Sat<93%) or days intubated 7 days
Secondary Length of stay in the intensive care unit The number of days in the intensive care unit 28 days
Secondary Time to discharge from hospital The number of days since admission to discharge 30 days
Secondary Occurrence of major adverse cardiovascular events The ocurrence of major adverse cardiovascular events (MACE): MI, stroke, CHF, PCI, death from cardiovascular disease will be studied. 7 days
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure